Results

INCENTIVE results that are public will be made available here and at the INCENTIVE Zenodo community (https://zenodo.org/communities/incentive/).

Publications

• Anderson AM, Tjärnhage E, Hinke DM, Braathen R, Grødeland G, Bogen B. DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection. Mol. Ther. Nucleic Acids. 2026 Mar12;37(1). doi: 10.1016/j.omtn.2025.102814.
• Uno N, Ross TM. Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase. Hum. Vaccin. Immunother. 2025 Dec11;21(1). doi: 10.1080/21645515.2025.2599611.
• Trieu MC, Bansal A, Sævik M. et al. Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers. npj Vaccines. 2025 Sep29;10(213). doi: 10.1038/s41541-025-01259-x.
• Naoko Uno, Thomas Ebensen, Carlos A Guzman, Ted M Ross. Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses. J Virol. 2024 Sep 17;98(9):e0035424. doi: 10.1128/jvi.00354-24.
• Hoen L, Lartey S, Zhou F, Pathirana RD, Krammer F, Mohn KG-I, Cox RJ, Brokstad KA. Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine. Vaccines. 2024 Aug1;12(8):864. doi: 10.3390/vaccines12080864.
• Naoko Uno, Ted M Ross. Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses. 
  Sci Rep. 2024 Jan 16;14(1):1440. doi: 10.1038/s41598-023-51024-0.
• Ekanger CT, Zhou F, Bohan D, Lotsberg ML, Ramnefjell M, Hoareau L, Røsland GV, Lu N, Aanerud M, Gärtner F, Salminen PR, Bentsen M, Halvorsen T, Ræder H, Akslen LA, Langeland N, Cox R, Maury W, Stuhr LEB, Lorens JB and Engelsen AST. Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. Front. Cell. Infect. Microbiol. 2022 Mar14;12:841447. doi: 10.3389/fcimb.2022.841447.
• Ertesvåg NU, Cox RJ, Lartey SL et al. Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. npj Vaccines. 2022 Jun24;7(67). doi: 10.1038/s41541-022-00490-0.
• Fjelltveit EB, Cox RJ, Østensjø J, Blomberg B, Ebbesen MH, Langeland N, Mohn KGI. Point-of-Care Influenza Testing Impacts Clinical Decision, Patient Flow, and Length of Stay in Hospitalized Adults. J. Infect. Dis. 2022 July1;226(1). doi: 10.1093/infdis/jiaa690.
• Bansal A, Trieu M-C, Mohn KGI and Cox RJ. Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. Front. Immunol. 2021 Oct6;12:744774. doi: 10.3389/fimmu.2021.744774.
• Hansen L, Zhou F, Amdam H, Trieu M-C and Cox RJ. Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers. Front. Immunol. 2021 Oct14;12:748264. doi: 10.3389/fimmu.2021.748264.
• Zhou F, Hansen L, Pedersen G, Grødeland G and Cox R. Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. Front. Immunol. 2021 Nov23;12:747774. doi: 10.3389/fimmu.2021.747774.
• Carlos A Guzman. Next Generation Influenza Vaccines: Looking into the Crystal Ball. Vaccines (Basel). 2020 Aug 21;8(3):464. doi: 10.3390/vaccines8030464.
• Madsen A, Cox RJ. Prospects and Challenges in the Development of Universal Influenza Vaccines. Vaccines. 2020; 8(3):361. doi: 10.3390/vaccines8030361.